INOVIO PHARMACEUTICALS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
INOVIO PHARMACEUTICALS INC. - More news...
INOVIO PHARMACEUTICALS INC. - More news...
- INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
- INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023
- INOVIO Reports Inducement Grants Under Inducement Plan
- INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)
- INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates
- INOVIO Provides an Update on Lassa Fever and MERS Programs
- INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
- INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
- INOVIO to Report Third Quarter 2022 Financial Results on November 8, 2022
- INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis
- INOVIO Reports Inducement Grants Under Inducement Plan
- INOVIO to Present at the H.C. Wainwright 24th Annual Global Investment Conference
- INOVIO Reports Financial Results and Highlights for the Second Quarter 2022
- INOVIO to Report Second Quarter 2022 Financial Results on August 9, 2022
- INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
- INOVIO Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer
- INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo® (cemiplimab) in Patients with Newly Diagnosed GBM at ASCO Annual Meeting 2022
- INOVIO to Present at Jefferies 2022 Healthcare Conference
- Thinking about buying stock in Neurometrix, Grab, SIGA Technologies, Inovio Pharmaceuticals, or Roblox?
- INOVIO Announces the Appointment of Jacqueline Shea, Ph.D., as Chief Executive Officer
- INOVIO Reports First Quarter 2022 Financial Results and Program Developments
- INOVIO to Report First Quarter 2022 Financial Results on May 10, 2022
- INOVIO to Present at Oppenheimer's 32nd Annual Healthcare Conference
- INOVIO Reports Fourth Quarter 2021 and Year-End Financial Results
- INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022
- INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
- INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
- Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceuticals, Beyondspring, or Inovio Pharmaceuticals?
- INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
